2012

Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT).

Top

Exclusive! Expert commentary webcast from Vivian Fonseca, MD, on this post-hoc analysis of VADT. Saremi A, Bahn G, Reaven PD; for the VADT Investigators. Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). Diabetes Care. 2012;35:2390-2392. Cross-sectional data from the Veterans Affairs Diabetes Trial (VADT) showed that participants with coronary artery or abdominal aortic calcification had an increased prevalence of cardiovascular disease, including peripheral artery disease and coronary artery disease.

Vital signs: awareness and treatment of uncontrolled hypertension among adults—United States, 2003–2010

Top

Centers for Disease Control and Prevention. Vital signs: awareness and treatment of uncontrolled hypertension among adults—United States, 2003–2010. MMWR Morb Mortal Wkly Rep. 2012;61(35);703-709. Data from the National Health and Nutrition Examination Survey (NHANES) 2003-2010 were analyzed to assess the prevalence of hypertension awareness and treatment among United States adults.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

NHANES: Obesity Prevalence and BMI Trends Among US Adults, 2009-2010

Top

Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-497. The National Health and Nutrition Examination Survey (NHANES) is a nationally representative sample of US civilian noninstituationalized population. The survey has run continuously since 1999, with data released in 2-year cycles.

BLOOM-DM: Efficacy, Safety of Lorcaserin for Weight Loss Among Those with Type 2 Diabetes

Top

O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426-1436. The Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus (BLOOM-DM) study was a randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of lorcaserin (administered in conjunction with a lifestyle modification program) for weight loss among those with type 2 diabetes.

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

Top

Sattar N, Preiss D, Murrary HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742. Sattar and colleagues conducted a meta-analysis to assess whether a relationship between statin use and development of diabetes exists.

SEQUEL: Longer-Term Safety, Efficacy of Phentermine + Topiramate for Weight Reduction Among Overweight or Obese Individuals with Cardiometabolic Disease

Top

Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308. The SEQUEL study, an extension of the CONQUER study,1 was a double-blind, placebo-controlled study that evaluated the longer-term efficacy and safety of once-daily, controlled-release phentermine plus topiramate, as an adjunct to lifestyle modification, among overweight and obese subjects with cardiometabolic disease.

Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes: ACCORD BP Trial

Top

Exclusive! Expert commentary from Henry Ginsberg, MD, on this post-hoc analysis of ACCORD BP. Barzilay JI, Howard AG, Evans GW, et al. Intensive blood pressure treatment does not improve cardiovascular outcomes in centrally obese hypertensive individuals with diabetes the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Blood Pressure Trial. Diabetes Care. 2012;35(7):1401-1405.

1 2 3 4 5 6 7 8 9 10  ... Next